A Phase 1 interventional study of Telmisartan/Amlodipine Combination Tablet and Amlodipine Monocomponent in Hypertension, sponsored by Boehringer Ingelheim. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-28.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 67th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2011, is the only one in phase 1, and was the 61st registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 381 across the 74 interventional studies, 3,252 across the 48 observational. Of the 120 that completed or were terminated, 41 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 122 studies in Hypertension by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be an open-label, randomized, two-treatment, two-period, two-sequence crossover study to evaluate the bioequivalence of the amlodipine component of Boehringer Ingelheim Pharma GmbH \& Co. KGs 80 mg telmisartan/10 mg amlodipine fixed dose combination tablet to the corresponding mono-component amlodipine tablets, 10 mg (Pfizers Norvasc).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females who participate in this study must either:
Exclusion criteria:
Donation or loss of whole blood:
Use of any drugs known to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telmisartan/Amlodipine medium fixed dose combination tablet once daily.
Drug: Telmisartan/Amlodipine Combination Tablet
Amlodipine Monocomponent 10mg tablet once daily
Drug: Amlodipine Monocomponent
Combination Tablet
Active Comparator
Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)
Area under the analyte concentration versus time curve from time zero to 72 hours as calculated by the linear trapezoidal method
Time frame: Day 1, Day 22
Maximum Observed Plasma Concentration (Cmax) of Amlodipine
Time frame: Day 1, Day 22
Time of Maximum Concentration of Amlodipine (TMAX)
Time of maximum measured amlodipine concentration over the zero to 72 hour sampling period
Time frame: Day 1, Day 22
| Milestone | Telm/Amlo 80 mg/10 mg First, Then Telm 80 mg + Amlo 10 mg | Telm 80 mg + Amlo 10 mg First, Then Telm/Amlo 80 mg/10 mg |
|---|---|---|
| Started | 14 | 14 |
| Completed | 13 | 13 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Milestone | Telm/Amlo 80 mg/10 mg First, Then Telm 80 mg + Amlo 10 mg | Telm 80 mg + Amlo 10 mg First, Then Telm/Amlo 80 mg/10 mg |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 13 |
| Not completed | 0 | 0 |
| Milestone | Telm/Amlo 80 mg/10 mg First, Then Telm 80 mg + Amlo 10 mg | Telm 80 mg + Amlo 10 mg First, Then Telm/Amlo 80 mg/10 mg |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 13 |
| Not completed | 0 | 0 |
Area under the analyte concentration versus time curve from time zero to 72 hours as calculated by the linear trapezoidal method
| nanograms*hour/milliliter | Telm/Amlo 80 mg/10 mg | Telm 80 mg + Amlo 10 mg |
|---|---|---|
| Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72) | 260.7971 ± 60.8717 | 276.6315 ± 66.1935 |
| nanograms/milliliter | Telm/Amlo 80 mg/10 mg | Telm 80 mg + Amlo 10 mg |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Amlodipine | 6.7465 ± 1.3354 | 7.2258 ± 1.6549 |
Time of maximum measured amlodipine concentration over the zero to 72 hour sampling period
| hours | Telm/Amlo 80 mg/10 mg | Telm 80 mg + Amlo 10 mg |
|---|---|---|
| Time of Maximum Concentration of Amlodipine (TMAX) | 6.69 ± 1.95 | 6.12 ± 1.40 |
Collected over 30 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Telm/Amlo 80 mg/10 mg | — | 0/27 (0%) | 3/27 (11.1%) |
| Telm 80 mg + Amlo 10 mg | — | 0/27 (0%) | 3/27 (11.1%) |
| Event | Telm/Amlo 80 mg/10 mg | Telm 80 mg + Amlo 10 mg |
|---|---|---|
| Blood urine presentRenal and urinary disorders | 1/27 | 2/27 |
| HeadacheNervous system disorders | 2/27 | 1/27 |
| Urine abnormalityRenal and urinary disorders | 0/27 | 2/27 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 39 ± 9 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 1 |
| Male | 27 |
| Race/Ethnicity, Customized(participants) | Entire Study Population |
|---|---|
| Hispanic/Latino | 7 |
| Asian | 3 |
| Black/African American | 6 |
| White | 12 |
| Height(centimeter) | Entire Study Population |
|---|---|
| Mean | 173.1 ± 7.1 |
| Weight(kilogram) | Entire Study Population |
|---|---|
| Mean | 80.3 ± 9.9 |
| Body Mass Index(kilogram / square meter) | Entire Study Population |
|---|---|
| Mean | 26.7 ± 2.5 |
The record gives a start of Jan 2011 and a primary completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.